Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Heat Biologics stock

Own Heat Biologics stock in just a few minutes.

Posted

Fact checked

Heat Biologics, Inc is a biotechnology business based in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Heat Biologics employs 36 staff and has a trailing 12-month revenue of around USD$3.5 million.

How to buy shares in Heat Biologics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Heat Biologics Find the stock by name or ticker symbol: HTBX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heat Biologics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Heat Biologics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Heat Biologics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Heat Biologics share price

Use our graph to track the performance of HTBX stocks over time.

Heat Biologics shares at a glance

Information last updated 2020-09-24.
52-week rangeUSD$0.195 - USD$4.3
50-day moving average USD$1.4406
200-day moving average USD$1.073
Wall St. target priceUSD$5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.654

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Heat Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heat Biologics price performance over time

Historical closes compared with the last close of $N/A

1 week (2020-09-17) -100.00%
1 month (2020-08-27) -100.00%
3 months (2020-06-26) -100.00%
6 months (2020-03-26) -100.00%
1 year (2019-09-26) -100.00%
2 years (2018-09-26) -100.00%
3 years (2017-09-26) -100.00%
5 years (2015-09-25) -100.00%

Heat Biologics financials

Revenue TTM USD$3.5 million
Gross profit TTM USD$-9,964,500
Return on assets TTM -25.3%
Return on equity TTM -59.43%
Profit margin 0%
Book value $0.434
Market capitalisation USD$194.7 million

TTM: trailing 12 months

Shorting Heat Biologics shares

There are currently 7.8 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 53% up from 5.1 million last month.

There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.

Heat Biologics's "short interest ratio" (SIR)

Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 18.2 million). Heat Biologics's SIR currently stands at 0.43. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 430 shares are currently held short.

However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 50 shares are currently held short) or 0.0515% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.

Find out more about how you can short Heat Biologics stock.

Heat Biologics share dividends

We're not expecting Heat Biologics to pay a dividend over the next 12 months.

Have Heat Biologics's shares ever split?

Heat Biologics's shares were split on a 1:10 basis on 22 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.

Heat Biologics share price volatility

Over the last 12 months, Heat Biologics's shares have ranged in value from as little as $0.195 up to $4.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.4331. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).

Heat Biologics overview

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site